Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016, provides an overview of the Hematopoietic Stem Cell Transplantation (Immunology) pipeline landscape.

Hematopoietic stem cell transplantation (HSCT) involves the intravenous (IV) infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. Predisposing risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Treatment includes immunosuppressive drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 3 and 1 respectively for Hematopoietic Stem Cell Transplantation.

Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation (Immunology).
- The pipeline guide reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hematopoietic Stem Cell Transplantation (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hematopoietic Stem Cell Transplantation (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hematopoietic Stem Cell Transplantation Overview 7
Therapeutics Development 8
Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview 8
Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies 9
Hematopoietic Stem Cell Transplantation - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Hematopoietic Stem Cell Transplantation - Products under Development by Companies 12
Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development 13
Actinium Pharmaceuticals, Inc. 13
Athersys, Inc. 14
Bellicum Pharmaceuticals, Inc. 15
Cell2B S.A. 16
Celldex Therapeutics, Inc. 17
Kiadis Pharma N.V. 18
Novartis AG 19
P2D Bioscience 20
Taiga Biotechnologies, Inc. 21
Targazyme, Inc. 22
Hematopoietic Stem Cell Transplantation - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ATIR-101 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
BPX-401 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Casin - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CDX-301 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CordSafe - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
HSC-835 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Iomab-B - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
PF-05285401 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
TBX-1400 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
TXA-127 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
TZ-101 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Hematopoietic Stem Cell Transplantation - Dormant Projects 68
Hematopoietic Stem Cell Transplantation - Discontinued Products 69
Hematopoietic Stem Cell Transplantation - Product Development Milestones 70
Featured News & Press Releases 70
Jun 30, 2016: Kiadis Pharma Orphan Drug Designation for ATIR101 further expanded to include treatment in a hematopoietic stem cell transplantation 70
May 18, 2016: Kiadis Pharma presents multiple sets of data at the International Society for Cellular Therapy 2016 Annual Meeting 70
Apr 25, 2016: Actinium to Host Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B 72
Apr 06, 2016: Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B 72
Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101 74
Mar 30, 2016: Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients 76
Mar 29, 2016: Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR101 76
Mar 08, 2016: Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B 77
Feb 20, 2016: Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting 77
Feb 02, 2016: Actinium Pharmaceuticals Announces Participation at Upcoming Annual Meeting of Pre-Eminent Blood and Marrow Transplant Organization 78
Nov 30, 2015: Actinium to Present on Iomab-B at 8th Annual LD Micro Main Event Conference on December 2, 2015 79
Apr 23, 2015: Targazyme Announces FDA Concurrence On Targazyme's Special Protocol Assessment For A Planned Phase 3 Registration Trial For The Treatment Of Patients With Hematologic Malignancie 79
Mar 17, 2015: Targazyme and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation 80
Feb 10, 2015: Targazyme Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation 80
Sep 25, 2014: Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables

Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 13
Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H2 2016 14
Hematopoietic Stem Cell Transplantation - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 15
Hematopoietic Stem Cell Transplantation - Pipeline by Cell2B S.A. , H2 2016 16
Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H2 2016 17
Hematopoietic Stem Cell Transplantation - Pipeline by Kiadis Pharma N.V., H2 2016 18
Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H2 2016 19
Hematopoietic Stem Cell Transplantation - Pipeline by P2D Bioscience, H2 2016 20
Hematopoietic Stem Cell Transplantation - Pipeline by Taiga Biotechnologies, Inc., H2 2016 21
Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Hematopoietic Stem Cell Transplantation - Dormant Projects, H2 2016 68
Hematopoietic Stem Cell Transplantation - Discontinued Products, H2 2016 69